Published in Biotech Business Week, January 3rd, 2005
In exchange, Guilford will obtain full ownership of the worldwide intellectual property rights to AQUAVAN Injection, a novel sedative/hypnotic currently in phase III clinical testing.
The ProQuest acquisition supersedes a technology license agreement signed between the two companies in March 2000, under which Guilford obtained worldwide...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.